Washington – Blue Cross Blue Shield Association Senior Vice President, Office of Policy and Representation, Justine Handelman issued the following statement today in response to President Trump’s initiative to address the high cost of prescription drugs:
“We believe that everyone should have timely access to safe, effective and affordable prescription medicines, and we’re encouraged by the administration’s steps to promote competition and speed the entry of generic and other lower-cost drugs to the market. We look forward to evaluating specific proposals as they become available, and we will continue to work with the administration and Congress to reduce barriers to competition and consumer choice, increase transparency, promote innovation and strengthen patient education so that people can access the drugs they need at a more affordable price.”
Additional prescription drug price reforms should:
• Continue to reduce obstacles that limit competition, consumer choice and patient access to new, lower-cost drugs
• Be examined for their impact on families and seniors, specifically with respect to out-of-pocket costs and premiums
• Promote greater transparency and information-sharing regarding both the price and effectiveness of drugs
To learn more about BCBSA’s proposals on how to address high prescription drug prices, visit https://www.bcbs.com/issues-indepth/providing-access-to-safe-effective-and-affordable-prescriptions.